ArticleHaematologica2015

Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.

Massimiliano Bonifacio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.